PAI-1在膀胱癌中的功能和机制的研究进展

doi:10.3760/cma.j.cn441417-20241113-14005

摘要/Abstract

摘要：

纤溶酶原激活物抑制剂-1（plasminogen activator inhibitor-1，PAI-1）属于丝氨酸蛋白酶抑制剂超家族成员之一，是发挥多种细胞效应的多效性因子，许多细胞效应潜在地与肿瘤的发生发展有关，包括细胞迁移、侵袭、黏附和血管生成，为潜在的治疗方法和新药物的开发奠定了基础。PAI-1在许多类型的癌症中过表达被发现是预后不良的一个指标。研究表明，PAI-1可作为潜在预测性生物标志物和治疗靶点应用于膀胱癌的临床诊疗中。本文就PAI-1在膀胱癌中的功能和机制进行探讨。

关键词: 纤溶酶原激活物抑制剂-1, , 膀胱癌, , 肿瘤增殖, , 肿瘤侵袭

Abstract:

Plasminogen activator inhibitor-1 (PAI-1), a member of the serine protease inhibitor superfamily, is a pleiotropic factor that plays a variety of cellular effects, many of which are potentially related to the occurrence and development of tumors, including cell migration, invasion, adhesion, and angiogenesis, laying the foundation for potential therapeutics and the development of new drugs. PAI-1 over-expression in many types of cancers has been found to be an indicator of poor prognosis. Studies suggest that PAI-1 can be used as a potential predictive biomarker and therapeutic target in the clinical treatment of bladder cancer. In this paper, the function and mechanism of PAI-1 in bladder cancer are discussed.

Key words: Plasminogen activator inhibitor-1, , Bladder cancer, , Tumor proliferation, , Tumor invasion

刘帅妹侯彦强.

PAI-1在膀胱癌中的功能和机制的研究进展 [J]. 国际医药卫生导报, 2025, 31(14): 2310-2313.

Liu Shuaimei, Hou Yanqiang.

Research progress on function and mechanism of PAI-1 in bladder cancer [J]. International Medicine and Health Guidance News, 2025, 31(14): 2310-2313.

参考文献

[1]Tian W, Shore KT, Shah RB. Signifcant reduction of indeterminate (atypical) diagnosis after implementation of the paris system for reporting urinary cytology:a single-institution study of more than 27,000 cases[J]. Cancer Cytopathol, 2021, 129(2): 114-120. DOI: 10.1002/cncy.22349.

[2]Li S, Wei X, He J, et al. Plasminogen activator inhibitor-1 in cancer research[J]. Biomed Pharmacother, 2018, 105: 83-94. DOI: 10.1016/j.biopha.2018.05.119.

[3]Grossmann NC, Schuettfort VM, Pradere B. Further understanding of urokinase plasminogen activator overexpression in urothelial bladder cancer progression, clinical outcomes and poten- tial therapeutic targets[J]. Onco Targets Ther, 2021, 14: 315-324. DOI: 10.2147/OTT.S242248.

[4]Furuya H, Hayashi K, Shimizu Y, et al. Plasminogen activator inhibitor-2 (PAI-2) over-expression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N-(4- hydroxybutyl)-nitrosamine-induced bladder cancer mouse model[J]. J Transl Med, 2020, 18(1): 57. DOI: 10.1186/s12967-020-02239-6.

[5]Chen Y, Yang C, Li Y, et al. MiR145-5p inhibits proliferation of PMVECs via PAI-1 in experi- mental hepatopulmonary syndrome rat pulmonary microvascular hyperplasia[J]. Biol Open, 2019, 8(11): bio044800. DOI: 10.1242/bio.044800.

[6]Wang X, Bustos MA, Zhang X, et al. Downregulation of the ubiquitin-E3 ligase RNF123 promotes upregulation of the NF-kappaB1 target serpinE1 in aggressive glioblastoma tumors[J]. Cancers (Basel), 2020, 12: 1081. DOI: 10.3390/cancers12051081.

[7]Wilkins-Port CE,Ye Q, Mazurkiewicz JE, et al. TGF-beta1+EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1[J]. Cancer Res, 2009, 69: 4081-4091. DOI: 10.1158/0008-5472.

[8]Placencio VR, DeClerck YA. Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing[J]. Cancer Res, 2015, 75(15): 2969-2974. DOI: 10.1158/0008-5472.

[9]Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI-1 paradox in cancer:more than meets the eye[J]. Semin Thromb Hemost, 2013, 39(4): 382-391. DOI: 10.1055/s-0033-1338127.

[10]Furuya H, Sasaki Y, Chen R, et al. PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity[J]. Sci Rep, 2022, 12(1): 12186. DOI: 10.1038/s41598-022-16518-3.

[11]Hassan S, Blick T, Thompson EW, et al. Diversity of epithelial-mesenchymal phenotypes in circulating tumour cells from prostate cancer patient-derived xenograft models[J]. Cancers (Basel), 2021, 13(11): 2750. DOI: 10.3390/cancers13112750.

[12]Miyake M, Lawton A, Dai Y, et al. Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer[J]. BMC Cancer, 2014, 14: 86. DOI: 10.1186/1471-2407-14-86.

[13]Czekay RP, Aertgeerts K, Curriden SA, et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins[J]. J Cell Biol, 2003, 160(5): 781-791. DOI: 10. 1083/jcb.200208117.

[14]Kang J, Kim W, Kwon T, et al. Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cells[J]. Oncotarget, 2016, 7(17): 23961-23974. DOI: 10.18 632/oncotarget.8208.

[15]Valiente M, Obenauf AC, Jin X, et al. Serpins promote cancer cell survival and vascular co- option in brain metastasis[J]. Cell, 2014, 156(5): 1002-1016. DOI: 10.1016/j.cell.2014.01.040.

[16]Fuentealba RA, Liu Q, Kanekiyo T, et al. Low density lipoprotein receptor-related protein 1 promotes anti-apoptotic signaling in neurons by activating akt survival pathway[J]. J Biol Chem, 2009, 284(49): 34045-34053. DOI: 10.1074/jbc.M109.021030.

[17]McMahon B, Kwaan HC. The plasminogen activator system and cancer [J]. Pathophysiol Haemost Thromb, 2008, 36(3-4): 184-194. DOI: 10.1159/000175156.

[18]Biasella F, Strunz T, Kiel C, et al. Vitronectin and its interaction with PAI-1 suggests a functional link to vascular changes in AMD pathobiology[J]. Cells, 2022, 11(11): 1766. DOI: 10.3390/cells11111 766.

[19]Kubala MH, Punj V, Placencio-Hickok VR, et al. Plasminogen activator inhibitor-1 promotes the recruitment and polarization of macrophages in cancer[J]. Cell Rep, 2018, 25(8): 2177-2191.e7. DOI: 10.1016/j.celrep.2018.10.082.

[20]Villadsen SB, Bramsen JB, Ostenfeld MS, et al. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer[J]. Br J Cancer, 2012, 106(2): 366-374. DOI: 10.1038/bjc.20 11.520.Epub 2011 Nov 22.

[21]Wang D, Yang LY, Liu Z, et al. PAI-1 overexpression promotes invasion and migration of esophageal squamous carcinoma cells[J]. Yi Chuan, 2020, 42(3): 287-295. DOI:10.16288/j.yczz.19-334.

[22]Nakatsuka E, Sawada K, Nakamura K, et al. Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor,inhibits ovarian cancer peritoneal dissemination[J]. Oncotarget, 2017, 8(52): 89887-89902. DOI: 10.18632/oncotarget.20834.

[23]Magnussen S, Rikardsen OG, Hadler-Olsen E, et al. Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC) [J]. PLoS One, 2014, 9: e101895. DOI: 10.1371/journal.pone.0101895.

[24]von der Maase H, Sengelov L, Roberts JT, et al. Longterm survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer[J]. J Clin Oncol, 2005, 23: 4602-4608. DOI:10.1200/JCO.2005.07.757.

[25]Che Y, Wang J, Li Y, et al. Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance[J]. Cell Death Dis, 2018, 9(7): 759. DOI: 10.1038/s41419-018-0808-2.

[26]Tseng YJ, Lee CH, Chen WY, et al. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade[J]. J Invest Dermatol, 2021, 141(11): 2690-2698.e6. DOI: 10.1016/j.jid.2021.03.030.

[27]Duggan B, O'Rourke D, Anderson N, et al. Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific[J]. Front Oncol, 2022, 12: 1009014. DOI: 10.3389/fonc.2022.1009014.

[28]Masuda T, Nakashima T, Namba M, et al. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts[J]. J Cell Mol Med, 2019, 23(4): 2984-2994. DOI: 10.1111/jcmm.14205.

[29]Murakami K, Furuya H, Hokutan K, et al. Association of SNPs in the PAI1 gene with disease recurrence and clinical outcome in bladder cancer[J]. Int J Mol Sci, 2023, 24(5): 4943. DOI: 10.33 90/ijms24054943.